STTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Shattuck Labs Inc (STTK) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts, such as analyst optimism and a differentiated approach in its pipeline, the company's poor financial performance, lack of recent news, and neutral trading sentiment suggest it is better to hold off on investing until more favorable conditions or clearer signals emerge.
The technical indicators show mixed signals. The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 47.894, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the pre-market price is below the pivot level of 4.092, suggesting potential downside risk.
Piper Sandler initiated coverage with an Overweight rating and a $15 price target, citing a differentiated approach in its pipeline.
Upcoming Phase 1 data in Q2 2026 could act as a catalyst if results are positive.
Financial performance in Q3 2025 was poor, with revenue dropping by 66.63% YoY and net income declining by 39.69% YoY.
No recent news or significant trading trends from hedge funds, insiders, or Congress.
Pre-market price is down by 1.98%, indicating weak sentiment.
In Q3 2025, the company reported a significant decline in revenue (-66.63% YoY) and net income (-39.69% YoY). EPS also dropped by 57.58% YoY to -0.14. Despite a 100% gross margin, the overall financial performance is weak.
Piper Sandler has an Overweight rating with a $15 price target, citing high probability of success for its pipeline drug SL-325. Citi raised its price target to $4 but maintained a Neutral rating, reflecting cautious optimism.
